Bimekizumab in Plaque Psoriasis - Trial NCT06336343
Access comprehensive clinical trial information for NCT06336343 through Pure Global AI's free database. This Phase 4 trial is sponsored by Icahn School of Medicine at Mount Sinai and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Icahn School of Medicine at Mount Sinai
Timeline & Enrollment
Phase 4
Mar 01, 2024
Oct 31, 2025
Primary Outcome
Body Surface Area (BSA) of 1
Summary
The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab
 in individuals with moderate-to-severe psoriasis who have failed similar therapies.
 Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called
 interleukins (specifically, interleukins 17a and 17F), which are known to increase
 inflammation. This study will look at the effectiveness of bimekizumab in psoriasis patients
 that have failed previous therapies that target interleukin IL-17A or 23.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06336343
Non-Device Trial